Zacks Research Has Pessimistic View of DYAI FY2026 Earnings

Dyadic International Inc. (NASDAQ:DYAI) – Stock analysts at Zacks Research dropped their FY2026 earnings estimates for shares of Dyadic International in a research note issued on Friday, August 14th. Zacks Research analyst J. Vandermosten now expects that the biotechnology company will post earnings of ($0.15) per share for the year, down from their prior forecast of $0.13. The consensus estimate for Dyadic International’s current full-year earnings is $0.13 per share.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.02 million. Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.

Separately, Weiss Ratings raised shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Down 3.3%

Shares of DYAI opened at $0.74 on Thursday. Dyadic International has a twelve month low of $0.65 and a twelve month high of $1.60. The stock has a market cap of $26.93 million, a PE ratio of -3.21 and a beta of 1.12. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 4.08. The business’s 50-day moving average price is $0.97 and its 200-day moving average price is $0.86.

Institutional Investors Weigh In On Dyadic International

Several large investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the second quarter worth about $50,000. BlackRock Inc. purchased a new stake in shares of Dyadic International in the 2nd quarter valued at about $177,000. Geode Capital Management LLC boosted its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the last quarter. Marathon Capital Management boosted its position in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.